Clinical trial
Treatment Of Patients With Social Anxiety Disorder
NCT00397722 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00397722 |
|---|---|
| Title | Treatment Of Patients With Social Anxiety Disorder |
| Official title | Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Social Phobia |
| Intervention type | Drug |
| Interventions | GW876008, paroxetine |
| Enrollment | 299 |
| Start date | Nov 9, 2006 |
| Primary completion | Sep 5, 2007 |
| Completion | Sep 5, 2007 |
| First posted | Nov 9, 2006 |
| Last update posted | Jul 11, 2017 |
| Countries | Canada, Finland, Germany, Norway, South Africa, Sweden, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: